CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| 4.54 | |
| 4.75 | |
| - | |
| 4.7899 | |
| 4.5175 | |
| 2.57-7 | |
| 259 M | |
| 54 959 K | |
| 29 702 | |
| -0.25 | |
| 1.599 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise...
–First and only FDA-approved antimicrobial catheter lock solution in the U.S. –Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 202...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
